See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive guidance stating that delaying Cosentyx treatment after receiving the COVID-19 vaccine is necessary. However, it is recommended to consult with a healthcare provider for personalized advice.

The Centers for Disease Control and Prevention (CDC) provides guidelines for vaccinations and immunocompromised patients, but it does not specifically mention Cosentyx or similar biologic treatments in relation to the COVID-19 vaccine [1]. Cosentyx, a drug used to treat various autoimmune conditions, is a biologic drug that may affect the immune system [2].

It is important to note that the COVID-19 vaccines have been deemed safe and effective for the general population, including individuals taking biologic drugs [1]. The CDC recommends that people take the vaccine as soon as it is available to them, regardless of their biologic drug use [1].

In summary, while there is no specific guidance on delaying Cosentyx treatment after receiving the COVID-19 vaccine, it is recommended to consult with a healthcare provider for personalized advice. The COVID-19 vaccines have been deemed safe and effective for the general population, including individuals taking biologic drugs.

Sources:
[1] Centers for Disease Control and Prevention. (2021). COVID-19 Vaccines for Moderately to Severely Immunocompromised People. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>
[2] Drugs.com. (2021). Secukinumab. <https://www.drugs.com/secukinumab.html>
[3] DrugPatentWatch.com. (2021). Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>